SCHEMBL476912

SCHEMBL476912

CC1(C)OB(c2ccnc3ccccc23)OC1(C)C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NCF1 P14598 1/20 0.42
LOXL2 Q9Y4K0 1/20 0.40
AR P10275 1/20 0.39
LPL P06858 2/20 0.39
LIPG Q9Y5X9 2/20 0.39
HTR1A P08908 2/20 0.38
ADRA1D P25100 2/20 0.38
ADRA1A P35348 2/20 0.38
ADRA1B P35368 2/20 0.38
MAPT P10636 4/20 0.37
NPC1 O15118 1/20 0.37
TP53 P04637 1/20 0.37
RAB9A P51151 1/20 0.37
PTK2B Q14289 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
LMNA P02545 1/20 0.36
HSP90AA1 P07900 1/20 0.36
HSP90AB1 P08238 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30728959 1.00 NCF1 (0.42) NCF1LOXL2ARLPLLIPG
SCHEMBL29982045 0.89 MAPT (0.42) LPLLIPGMAPTSMN1; SMN2MEN1
SCHEMBL481508 0.89 MAPT (0.42) LPLLIPGMAPTSMN1; SMN2MEN1
SCHEMBL17531651 0.84 LPL (0.37) LPLLIPGKDM4E
SCHEMBL30835798 0.84 LPL (0.37) LPLLIPGKDM4E
SCHEMBL23347451 0.81 KDM4A (0.35) LPLLIPG
SCHEMBL16009625 0.80 LPL (0.35) LPLLIPGMAPTNPC1MEN1
SCHEMBL25606892 0.80 HTR1A (0.44) HTR1AADRA1DADRA1AADRA1BMAPT
SCHEMBL17531645 0.80 EGFR (0.34) LPLLIPG
SCHEMBL30682111 0.79 LPL (0.34) LPLLIPGMAPTNPC1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250109135-A1 NOVEL ISOINDOLINONE DERIVATIVE COMPOUNDS AS CASPASE INHIBITORS INNOVO THERAPEUTICS INC. (KR) 2025-04-03 US disclosed
EP-4461726-A1 NOVEL ISOINDOLINONE DERIVATIVE COMPOUNDS AS CASPASE INHIBITORS Innovo Therapeutics Inc. (KR) 2024-11-13 EP disclosed
US-20240309008-A1 IMIDAZOPYRIDAZINE AND IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2024-09-19 US disclosed
US-12030889-B2 Imidazopyridazine and imidazopyridine compounds and uses thereof INCYTE CORPORATION (US) 2024-07-09 US disclosed
US-11844268-B2 Organic compound and organic light-emitting element CANON KABUSHIKI KAISHA (JP) 2023-12-12 US disclosed
US-11844268-B2 Organic compound and organic light-emitting element CANON KABUSHIKI KAISHA (JP) 2023-12-12 US disclosed
WO-2023132606-A1 NOVEL ISOINDOLINONE DERIVATIVE COMPOUNDS AS CASPASE INHIBITORS 주식회사 이노보테라퓨틱스 2023-07-13 WO disclosed
WO-2023132606-A1 NOVEL ISOINDOLINONE DERIVATIVE COMPOUNDS AS CASPASE INHIBITORS 주식회사 이노보테라퓨틱스 2023-07-13 WO disclosed
EP-3313828-B1 METALLO-BETA-LACTAMASE INHIBITORS MERCK SHARP & DOHME LLC (US) 2023-07-12 EP disclosed
US-20220315595-A1 IMIDAZOPYRIDAZINE AND IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2022-10-06 US disclosed
EP-2411398-A1 METHOD FOR MANUFACTURING A BORONIC ACID ESTER COMPOUND Sumitomo Chemical Company, Limited (JP) 2012-02-01 EP disclosed
US-8034944-B2 Benzofluoranthene compound and organic light-emitting device using the compound CANON KABUSHIKI KAISHA (JP) 2011-10-11 US disclosed
US-8034944-B2 Benzofluoranthene compound and organic light-emitting device using the compound CANON KABUSHIKI KAISHA (JP) 2011-10-11 US disclosed
US-8034944-B2 Benzofluoranthene compound and organic light-emitting device using the compound CANON KABUSHIKI KAISHA (JP) 2011-10-11 US disclosed
WO-2010138589-A1 BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE GENENTECH, INC. (US) 2010-12-02 WO disclosed
US-20100305096-A1 BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE GENENTECH, INC. 2010-12-02 US disclosed
WO-2010110782-A1 METHOD FOR MANUFACTURING A BORONIC ACID ESTER COMPOUND SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-09-30 WO disclosed
US-20090278118-A1 BENZOFLUORANTHENE COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE USING THE COMPOUND CANON KABUSHIKI KAISHA (JP) 2009-11-12 US disclosed
US-20090278118-A1 BENZOFLUORANTHENE COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE USING THE COMPOUND CANON KABUSHIKI KAISHA (JP) 2009-11-12 US disclosed
US-20090278118-A1 BENZOFLUORANTHENE COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE USING THE COMPOUND CANON KABUSHIKI KAISHA (JP) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11844268-B2 Organic compound and organic light-emitting element OR51E2, OR10J3, NR2E3 NCF1 1414/4885LOXL2 2506/4885AR 1124/4885
US-20220315595-A1 IMIDAZOPYRIDAZINE AND IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF ALK, ABL2, ACVR2A NCF1 1634/4885LOXL2 304/4885AR 1928/4885
US-20250109135-A1 NOVEL ISOINDOLINONE DERIVATIVE COMPOUNDS AS CASPASE INHIBITORS CASP1, CASP8, CASP2 NCF1 357/4885LOXL2 3449/4885AR 2983/4885
US-20090278118-A1 BENZOFLUORANTHENE COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE USING THE COMPOUND XDH, XPO6, PAX3 NCF1 582/4885LOXL2 165/4885AR 4018/4885
US-12030889-B2 Imidazopyridazine and imidazopyridine compounds and uses thereof ALK, ABL2, ACVR2A NCF1 1634/4885LOXL2 304/4885AR 1928/4885
US-20240309008-A1 IMIDAZOPYRIDAZINE AND IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF ALK, ABL2, ACVR2A NCF1 1634/4885LOXL2 304/4885AR 1928/4885
US-20100305096-A1 BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE PIK3CA, PIK3R2, PIK3CD NCF1 388/4885LOXL2 3162/4885AR 2576/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.